Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Neil Schauer

Neil Schauer

Schauer Biologics Consulting, LLC, USA

Title: Risk based development and manufacturing of biosimilars

Biography

Biography: Neil Schauer

Abstract

The development of biosimilars presents a unique risk profile to biopharmaceutical companies when compared to proprietary biologics development.  This risk profile will be examined and used to explain why biosimilars must be developed and manufactured differently than originator molecules, in order to insure commercial success. For biosimilars, commercial endpoint oriented process development should start earlier for biosimilars than for originator products. To buy down risk, At-Scale manufacturing may be desirable as early as nonclinical / phase I manufacturing.